Jazz Pharmaceuticals (JAZZ) Cost of Revenue (2010 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly Cost of Revenue of $134.1 million for Q1 2026, up 28.2% year-over-year from $104.6 million in Q1 2025, and down 12.65% quarter-over-quarter from $153.5 million in Q4 2025.
Jazz Pharmaceuticals (JAZZ) Cost of Revenue (2010 - 2026) Analysis & Trends
Jazz Pharmaceuticals' Cost of Revenue history runs 17 years deep, the most recent figure standing at $134.1 million for Q1 2026.
- In Q1 2026, Cost of Revenue rose 28.2% year-over-year to $134.1 million; the TTM figure through Mar 2026 stood at $532.8 million (up 17.14% YoY), while the FY2025 annual figure was $503.3 million, up 12.92% from the prior year.
- Cost of Revenue for Q1 2026 stood at $134.1 million, down from $153.5 million in the prior quarter.
- The five-year high for Cost of Revenue was $167.4 million in Q4 2022, with the low at $95.5 million in Q1 2024.
- The 5-year median for Cost of Revenue is $116.3 million (2025), against an average of $121.1 million.
- The sharpest annual moves came in 2022 and 2023: Cost of Revenue soared 186.85% in 2022, then slumped 35.92% in 2023.
- Jazz Pharmaceuticals' Cost of Revenue stood at $167.4 million in 2022, then tumbled by 35.92% to $107.2 million in 2023, then gained by 20.02% to $128.7 million in 2024, then climbed by 19.28% to $153.5 million in 2025, then decreased by 12.65% to $134.1 million in 2026.
- Business Quant data shows JAZZ's Cost of Revenue at $134.1 million in Q1 2026, $153.5 million in Q4 2025, and $128.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 145.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 174.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.18 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 298.26 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn | 116.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 116.40 Mn |
| Jun 30, 2026 | 116.40 Mn |
| Mar 31, 2026 | 134.10 Mn |
| Mar 31, 2026 | 134.10 Mn |
| Dec 31, 2025 | 153.53 Mn |
| Dec 31, 2025 | 153.53 Mn |
| Sep 30, 2025 | 128.88 Mn |
| Sep 30, 2025 | 128.88 Mn |
| Jun 30, 2025 | 116.27 Mn |
| Jun 30, 2025 | 116.27 Mn |
| Mar 31, 2025 | 104.60 Mn |
| Mar 31, 2025 | 104.60 Mn |
| Dec 31, 2024 | 128.71 Mn |
| Dec 31, 2024 | 128.71 Mn |
| Sep 30, 2024 | 111.61 Mn |
| Sep 30, 2024 | 111.61 Mn |
| Jun 30, 2024 | 109.90 Mn |
| Jun 30, 2024 | 109.90 Mn |
| Mar 31, 2024 | 95.49 Mn |
| Mar 31, 2024 | 95.49 Mn |